公开(公告)号：US20190062751A1

公开(公告)日：2019-02-28

申请号：US15569559

申请日：2016-04-22

Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY

Inventor： Kiyoko FUKAMI ,  Reiko SATOW

IPC: C12N15/113 ,  A61P35/04 ,  C12Q1/6886

CPC classification number: C12N15/1135 ,  A61K31/713 ,  A61K45/00 ,  A61K48/00 ,  A61P35/04 ,  C07K14/4702 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158

Abstract: The present invention provides an anti-tumor agent and a suppressor for suppressing malignant transformation such as acquisition of metastatic ability or acquisition of apoptosis resistance of a tumor cell. The present invention provides a tumor cell malignant transformation suppressor, including a substance suppressing or inhibiting Zic5 gene functions as an active ingredient to suppress or inhibit acquisition of metastatic ability or acquisition of apoptosis resistance of a tumor cell; a method of suppressing tumor cell malignant transformation of animals other than humans, including suppressing or inhibiting Zic5 gene functions to suppress or inhibit acquisition of metastatic ability or acquisition of apoptosis resistance of a tumor cell; an anti-tumor agent including a substance suppressing or inhibiting Zic5 gene functions as an active ingredient, in which the agent is used in prostate cancer therapy; and a marker for tumor cell malignancy consisting of the expression level of Zic5 gene.

公开(公告)号：US20240238241A1

公开(公告)日：2024-07-18

申请号：US18292496

申请日：2022-07-28

Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY

Inventor： Kiyoko FUKAMI ,  Reiko SATOW

IPC: A61K31/365 ,  A61K31/133 ,  A61K31/366 ,  A61K31/407 ,  A61K31/585 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K31/365 ,  A61K31/133 ,  A61K31/366 ,  A61K31/407 ,  A61K31/585 ,  A61P35/00 ,  C12N15/113

Abstract: The present invention provides a pharmaceutical composition that suppresses cell proliferation and has an anti-cancer effect with respect to pancreatic cancer and bile duct cancer. The present invention relates to a pharmaceutical composition containing, as an active ingredient, a substance that reduces an intracellular content of a ZIC5 protein, where the composition is used for treatment of pancreatic cancer or bile duct cancer; the pharmaceutical composition further containing an anti-cancer agent other than the substance that reduces the intracellular content of the ZIC5 protein; and the pharmaceutical composition further containing an anti-cancer agent other than the substance that reduces the intracellular content of the ZIC5 protein.